These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28390438)

  • 1. High fluoroquinolone MIC is associated with fluoroquinolone treatment failure in urinary tract infections caused by fluoroquinolone susceptible Escherichia coli.
    Rattanaumpawan P; Nachamkin I; Bilker WB; Roy JA; Metlay JP; Zaoutis TE; Lautenbach E;
    Ann Clin Microbiol Antimicrob; 2017 Apr; 16(1):25. PubMed ID: 28390438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for ambulatory urinary tract infections caused by high-MIC fluoroquinolone-susceptible Escherichia coli in women: results from a large case-control study.
    Rattanaumpawan P; Nachamkin I; Bilker WB; Roy JA; Metlay JP; Zaoutis TE; Lautenbach E;
    J Antimicrob Chemother; 2015 May; 70(5):1547-51. PubMed ID: 25630645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to fluoroquinolones and treatment failure/short-term relapse of community-acquired urinary tract infections caused by Escherichia coli.
    Gagliotti C; Buttazzi R; Sforza S; Moro ML;
    J Infect; 2008 Sep; 57(3):179-84. PubMed ID: 18707763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of fluoroquinolone resistance in outpatient urinary Escherichia coli isolates.
    Johnson L; Sabel A; Burman WJ; Everhart RM; Rome M; MacKenzie TD; Rozwadowski J; Mehler PS; Price CS
    Am J Med; 2008 Oct; 121(10):876-84. PubMed ID: 18823859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental and clinical studies on fluoroquinolone-insusceptible Escherichia coli isolated from patients with urinary tract infections from 1994 to 2007.
    Wada K; Kariyama R; Mitsuhata R; Uehara S; Watanabe T; Monden K; Kumon H
    Acta Med Okayama; 2009 Oct; 63(5):263-72. PubMed ID: 19893602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective review of ceftriaxone versus levofloxacin for treatment of E. coli urinary tract infections.
    Wang SS; Ratliff PD; Judd WR
    Int J Clin Pharm; 2018 Feb; 40(1):143-149. PubMed ID: 29147962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact.
    Shin J; Kim J; Wie SH; Cho YK; Lim SK; Shin SY; Yeom JS; Lee JS; Kweon KT; Lee H; Cheong HJ; Park SH; Park DW; Ryu SY; Chung MH; Yoo S; Pai H
    Microb Drug Resist; 2012 Apr; 18(2):169-75. PubMed ID: 22400491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
    Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
    Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergence of fluoroquinolone resistance in Escherichia coli isolates at the department of clinical hematology.
    Zemkova M; Kotlarova J; Merka V; Cermak P; Vlcek J; Jebavy L
    New Microbiol; 2007 Oct; 30(4):423-30. PubMed ID: 18080678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy.
    Lautenbach E; Metlay JP; Bilker WB; Edelstein PH; Fishman NO
    Clin Infect Dis; 2005 Oct; 41(7):923-9. PubMed ID: 16142655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors and mechanisms of fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections.
    Yasufuku T; Shigemura K; Shirakawa T; Nakano Y; Tanaka K; Arakawa S; Kinoshita S; Nishimura K; Kawabata M; Fujisawa M
    Scand J Infect Dis; 2011 Feb; 43(2):83-8. PubMed ID: 20942776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for fluoroquinolone-resistant Escherichia coli in adults with community-onset febrile urinary tract infection.
    van der Starre WE; van Nieuwkoop C; Paltansing S; van't Wout JW; Groeneveld GH; Becker MJ; Koster T; Wattel-Louis GH; Delfos NM; Ablij HC; Leyten EM; Blom JW; van Dissel JT
    J Antimicrob Chemother; 2011 Mar; 66(3):650-6. PubMed ID: 21123286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating outcomes associated with revised fluoroquinolone breakpoints for Enterobacterales urinary tract infections: A retrospective cohort study.
    Benavides TM; Aden JK; Giancola SE
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):741-749. PubMed ID: 35224677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone-resistant Escherichia coli in the long-term care setting.
    Cohen AE; Lautenbach E; Morales KH; Linkin DR
    Am J Med; 2006 Nov; 119(11):958-63. PubMed ID: 17071164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for fluoroquinolone resistance in Enterococcus urinary tract infections in hospitalized patients.
    Rattanaumpawan P; Tolomeo P; Bilker WB; Fishman NO; Lautenbach E
    Epidemiol Infect; 2011 Jun; 139(6):955-61. PubMed ID: 20696087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between fluoroquinolone resistance and resistance to other antimicrobial agents among Escherichia coli urinary isolates in the outpatient setting: a national cross-sectional study.
    Hwang TJ; Hooper DC
    J Antimicrob Chemother; 2014 Jun; 69(6):1720-2. PubMed ID: 24521853
    [No Abstract]   [Full Text] [Related]  

  • 18. Risk factors for urinary tract infections due to ciprofloxacin-resistant Escherichia coli in a tertiary care urology department in Switzerland.
    Nicoletti J; Kuster SP; Sulser T; Zbinden R; Ruef C; Ledergerber B; Weber R
    Swiss Med Wkly; 2010; 140():w13059. PubMed ID: 20648400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.
    Rattanaumpawan P; Tolomeo P; Bilker WB; Fishman NO; Lautenbach E
    J Hosp Infect; 2010 Dec; 76(4):324-7. PubMed ID: 20643497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virulence genotypes and phylogenetic background of fluoroquinolone-resistant and susceptible Escherichia coli urine isolates from dogs with urinary tract infection.
    Johnson JR; Kuskowski MA; Owens K; Clabots C; Singer RS
    Vet Microbiol; 2009 Apr; 136(1-2):108-14. PubMed ID: 19019576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.